Home  /  Resource Library  /  TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMAS: SAFETY AND EFFICACY RESULTS FROM A PHASE 2 STUDY

TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMAS: SAFETY AND EFFICACY RESULTS FROM A PHASE 2 STUDY

EHA 2020: Results of a phase II study examining Tislelizumab for treatment of relapsed peripheral t-cell lymphomas.